alpha1at deficiency genetic disorder characterized low serum levels high risk pulmonary emphysema young age resulting surplus proteases mainly neutrophil elastase balanced iv augmentation clear affected patients benefit augmentation therapy safety data available examined NUMBER patients severe deficiency pulmonary emphysema receiving weekly iv infusions NUMBER mg x kg body addition regular medication progression disease assessed repeated lung function measurements particularly decline forced expiratory volume second deltafev1 patients alpha1at deficiency tolerated augmentation therapy adverse reactions deltafev1 NUMBER patients available data ml x stratified baseline fev1 decline ml NUMBER patients initial fev1 NUMBER ml NUMBER fev1 predicted normal p00008 remaining NUMBER patients initial fev1 NUMBER pred treatment iv patients severe deficiency feasible safe decline forced expiratory volume second related initial forced expiratory volume second deficient patients receiving augmentation therapy alpha1 antitrypsin alpha1 alpha1 long term long term alpha1 weight NUMBER alpha1 follow NUMBER yr NUMBER NUMBER NUMBER NUMBER NUMBER long term alpha1 antitrypsin alpha1 antitrypsin alpha1 antitrypsin NUMBER NUMBER NUMBER